Homeopathy 2006; 95(03): 123-130
DOI: 10.1016/j.homp.2006.04.003
Original Paper
Copyright © The Faculty of Homeopathy 2006

Double-blind, placebo-controlled homeopathic pathogenetic trials: Symptom collection and analysis

G Dominici
1  Centro Omeopatico Vescovio, p.zza Vescovio 7, Rome, Italy
P Bellavite
2  Dipartimento di Scienze Morfologico-Biomediche, Università di Verona, Italy
C di Stanislao
3  UOC di Dermatologia, Dipartimento di Medicina, ASL 04 L’Aquila, Italy
P Gulia
4  IRMSO, Istituto di Ricerca Medico, Scientifica Omeopatica, Rome, Italy
G Pitari
5  Dipartimento di Biologia di Base e Applicata, Università degli Studi di L’Aquila, via Vetoio 10, 67010 Coppito L’Aquila, Italy
› Institutsangaben

Verantwortlicher Herausgeber dieser Rubrik:
Weitere Informationen


Received14. März 2005
revised08. August 2005

accepted24. April 2006

26. Dezember 2017 (online)


Background: Homeopathic pathogenetic trials (provings) are fundamental to homeopathy. Since most of the data from available provings have not been statistically evaluated, it is unclear how specific reported symptoms are and how they differ from those reported by people taking placebo.

Method: We combine and analyse data from two different homeopathic pathogenic trials—including 10 and 11 provers, respectively, and both including 30% placebo—to test the null hypothesis that there is no significant difference between the number of symptoms in placebo and verum groups.

Results: The principal results were:

• Placebo reported less symptoms than verum groups.

• Symptom distribution according to predefined classes (common symptoms increased in intensity and/or duration-, cured, old, new and exceptional) was statistically different between placebo and verum group at a high level of significance (P<0.001). Compared to verum, placebo provers reported less new and old but more common (increased in duration or intensity) symptoms.

• Within repertory categories, other differences were detected.

• The two groups differ in terms of the duration of each symptom and kinetics of symptoms: most symptoms were more persistent in verum than in placebo groups and verum provers recorded a decreasing number of symptoms with time. Placebo provers did not show such a temporal pattern.

Conclusions: If confirmed by other studies these results would demonstrate the non-equivalence between homeopathic medicines in high dilution and placebo and contribute to the improvement of proving methodology and evaluation.